Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome

American Journal of Transplantation

Volumn 13, Issue 3, 2013, Pages 663-675

  Le Quintrec, M ^a,b   Zuber, J ^c   Moulin, B ^d   Kamar, N ^e,f   Jablonski, M ^c   Lionet, A ^g   Chatelet, V ^h   Mousson, C ⁱ   Mourad, G ^j   Bridoux, F ^k   Cassuto, E ^l   Loirat, C ^m   Rondeau, E ⁿ   Delahousse, M ^a   Fremeaux Bacchi V ^o  

^a FOCH HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d Service de Néphrologie et de Transplantation Rénale   (France)

^e CHU RANGUEIL   (France)

^f CHU PURPAN   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h CAEN UNIVERSITY HOSPITAL   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j LAPEYRONIE HOSPITAL   (France)

^k POITIERS UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF NICE   (France)

^m ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁿ HÔPITAL TENON   (France)

^o HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Acute rejection; atypical hemolytic and uremic syndrome; endothelial cell damage; mutations and polymorphisms in complement alternative pathway; renal transplantation; thrombotic microangiopathy

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; CYCLOSPORIN; ECULIZUMAB; FIBRINOGEN; HLA DR ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEMBRANE COFACTOR PROTEIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE HEART FAILURE; ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DIALYSIS; FEMALE; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPE; HEART INFARCTION; HEMOLYTIC UREMIC SYNDROME; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

EID: 84874417661     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12077     Document Type: Article

References (58)

1. Ruggenenti P, Noris M, Remuzzi G,. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60: 831-846.
2. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1: 88-99.
3. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859.
4. Zuber J, Le Quintrec M, Sberro-Soussan R, et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 7: 23-35.
5. Noris M, Remuzzi G,. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687.
6. Le Quintrec M, Roumenina L, Noris M, Fremeaux-Bacchi V,. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 2010; 36: 641-652.
7. Bienaime F, Dragon-Durey MA, Regnier, CH, Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010; 77: 339-349.
8. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003; 12: 3385-3395.
9. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006; 108: 1267-1279.
10. Fremeaux-Bacchi V, Arzouk N, Ferlicot S, Charpentier B, Snanoudj R, Durrbach A,. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: A role for endothelial microchimerism. Am J Transplant 2007; 7: 2047-2051.
11. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41: e84.
12. Fremeaux-Bacchi V, Kemp EJ, Goodship JA, et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: Evidence from two independent cohorts. J Med Genet 2005; 42: 852-856.
13. Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 4948-4952.
14. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104: 240-245.
15. Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 2150-2155.
16. Roumenina LT, Jablonski M, Hue C, et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009; 114: 2837-2845.
17. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563.
18. Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21: 2180-2187.
19. Jozsi M, Licht C, Strobel S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512-1514.
20. Ermini L, Goodship TH, Strain L, et al. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol 2012; 49: 640-648.
21. Heurich M, Martinez-Barricarte R, Francis NJ, et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A 2011; 108: 8761-8766.
22. Pickering MC, de Jorge EG, Martinez-Barricarte R, et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007; 204: 1249-1256.
23. Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL,. Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968-974.
24. Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000; 36: 844-850.
25. Sartelet H, Toupance O, Lorenzato M, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005; 5: 2441-2447.
26. Ulinski T, Charpentier A, Colombat M, et al. From humoral rejection to generalized thrombotic microangiopathy-role of acquired ADAMTS13 deficiency in a renal allograft recipient. Am J Transplant 2006; 6: 3030-3036.
27. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V,. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011; 365: 8-26.
28. Venables JP, Strain L, Routledge D, et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006; 3: e431.
29. Zhao J, Wu H, Khosravi M, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011; 7: e1002079.
30. Moake, JL,. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
31. Davin JC, Majoie C, Groothoff J, et al. Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation. Pediatr Nephrol 2011; 26: 155-157.
32. Loirat C, Macher MA, Elmaleh-Berges M, et al. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant 2010; 25: 3421-3425.
33. Sallee M, Daniel L, Piercecchi MD, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant 2010; 25: 2028-2032.
34. Lahlou A, Lang P, Charpentier B, et al. Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Cooperatif de l'Ile-de-France (GCIF). Medicine 2000; 79: 90-102.
35. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007; 18: 2392-2400.
36. Saland JM, Ruggenenti P, Remuzzi G,. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009; 20: 940-949.
37. Noris M, Remuzzi G,. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517-1523.
38. Chan MR, Thomas CP, Torrealba JR, et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis 2009; 53: 321-326.
39. Geelen, J, van den Dries, K, Roos, A, et al. A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatr Nephrol 2007; 22: 371-375.
40. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 2017-2025.
41. Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100: 12966-12971.
42. Richards A, Kathryn Liszewski M, Kavanagh D, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007; 44: 111-122.
43. Liszewski MK, Leung MK, Schraml B, Goodship TH, Atkinson JP,. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol Immunol 2007; 44: 1559-1568.
44. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T,: Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010; 36: 673-681.
45. Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6: 1488-1494.
46. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S,. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 1325-1329.
47. Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362: 1746-1748.
48. Zuber J, Le Quintrec M, Bertoye C, et al. the French Study Group for atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012; 8: 643-657.
49. Al-Akash SI, Almond PS, Savell VH, Jr., Gharaybeh SI, Hogue C,. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011; 26: 613-619.
50. Albertazzi V, Bonucchi D, De Amicis S, Americo C, Ghiandai G, Cappelli G,. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: Case report. Transplant Proc 2010; 42: 1352-1354.
51. Davin JC, Groothoff J, Gracchi V, Bouts A,. Long-term renal function under plasma exchange in atypical hemolytic uremic syndrome. Pediatr Nephrol 2011; 26: 1915-1916.
52. Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Fremeaux-Bacchi V, Steiger J,. Haemolytic uraemic syndrome caused by factor H mutation: Is single kidney transplantation under intensive plasmatherapy an option? Nephrol Dial Transplant 2009; 24: 3548-3551.
53. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC,. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42: 1058-1068.
54. Quan A, Sullivan EK, Alexander SR,. Recurrence of hemolytic uremic syndrome after renal transplantation in children: A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 2001; 72: 742-745.
55. Le Quintrec M, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8: 1694-1701.
56. Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LA, Wetzels JF,. Renal transplantation in patients with hemolytic uremic syndrome: High rate of recurrence and increased incidence of acute rejections. Transplantation 2003 76: 821-826.
57. Oyen O, Strom EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant 2006; 6: 412-418.
58. Zhou W, Medof ME, Heeger PS, Sacks S,. Graft-derived complement as a mediator of transplant injury. Curr Opin Immunol 2007; 19: 569-576.